Skip to main content
. 2022 Feb;13(1):163–170. doi: 10.21037/jgo-21-514

Table 2. Tumor response based on mutation status.

Variable KRAS mut Wild-type P value
Overall tumor reduction, median (range) 58% (−257–94%) 70% (53–100%) 0.04
ORR, n (%) 7 (64%) 13 (100%) 0.03
Conversion to resectability, n (%) 2 (18%) 8 (62%) 0.05
Progression free survival, months, median (95% CI) 8.9 (95% CI: 4.7–13.1) 9.8 (95% CI: 6.4–13.1) 0.68
Hepatic progression free survival, months, median (95% CI) 20.5 (95% CI: 6.1–34.9) 12.7 (95% CI: 5.6–19.8) 0.63

ORR, objective response rate.